Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
The amount of the proposed dividend is submitted for approval by the shareholders at the general meeting.Fully registered shareholders will be paid their dividend automatically by BNP Paribas, while holders of administered registered shares or bearer shares will be paid their dividend by the financial intermediary that manages their shares.The Board of Directors convened on February 5, 2020, and proposed a dividend of €3.15 per share.
Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/2 study to start in September, followed by a Phase 3 study by the end of 2020.
The General Meeting also renewed Laurent Attal, Carole Piwnica, Diane Souza and Thomas Südhof as Directors, ratified the co-opting of Paul Hudson and approved the appointment of Rachel Duan and Lise Kingo as Independent Directors in replacement of Suet-Fern Lee and Claudie Haigneré.
Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Australia Has Deadliest Day, Brazil Tops 100,000: Virus Upda... Key dates for ordinary shares April 28, 2020: Annual General Meeting
Sanofi Pasteur, the global vaccines business unit of the French drug maker Sanofi, has joined with a US government department to develop a novel COVID-19 coronavirus vaccine. Mexico’s Tourism Website Tripped Up by Strange Translations QAnon Is Running Amok, and the Time Has Come for Interventio... Forward-looking statements are statements that are not historical facts.
MTN Considers Sale of Stake in Iran Ride-Hailing App Snapp Exchange rate movements had a positive effect of 0.3 percentage points, mainly driven by the strength of the U.S. dollar and the Japanese yen, partially offset by the decrease in the Brazilian real and the Argentine peso. Mexico’s Tourism Website Tripped Up by Strange Translations
Buffett’s Grim View of Air Travel Realized in $10 Billion Ch...
Global clinical program underway to evaluate Kevzara ® in patients hospitalized with severe COVID-19. 10 arising from the profit of the sale of the Co's shareholding in Chiron Behring Vaccines Pvt. By continuing to browse this website, you agree to the use of such cookies. No drugs or vaccines have yet been approved for the novel coronavirus and related lung illness.Regeneron, which will be leading U.S.-based trials, will immediately begin enrolling patients across 16 sites, beginning with medical centers in New York, one of the Shares of Sanofi fell about 7% in Paris, while Regeneron declined 3.1% in trading in New York before a broader sell-off triggered a market-wide trading halt.The pathway the experimental treatment is targeting may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with Covid-19, the drugmakers said in a France’s Sanofi and Regeneron, based in Tarrytown, New York, will first evaluate how Kevzara impacts patients’ fevers and need for supplemental oxygen.
Updates with share-price information in fourth paragraph
QAnon Is Running Amok, and the Time Has Come for Interventio...
The drugmakers will also assess the improvement in longer-term outcomes including preventing death and reducing the need for mechanical ventilation, supplemental oxygen and hospitalization.In order to quickly initiate the clinical trial for patients severely impacted by the novel coronavirus, the drugmakers worked closely with the U.S. Food and Drug Administration and the Biomedical Advanced Research and Development Authority, said Regeneron Co-Founder and President George D. Yancopoulos.In an initial, non-peer reviewed Chinese trial of 21 patients, scientists identified preliminary evidence that IL-6 may play an important role in driving the inflammatory immune response that causes acute respiratory distress in patients critically ill from Covid-19.
Regeneron launches clinical trials in New York and across U.S. Le Conseil d’administration, réuni le 5 février 2020, a proposé un dividende de €3,15 par action, soit la 26ème année consécutive de croissance du dividende. Australia Has Deadliest Day, Brazil Tops 100,000: Virus Upda...